Global RNAi Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global RNAi Drugs Market Research Report 2024
It refers to the highly conservative, double stranded RNA induced, highly specific degradation of homologous mRNA in the evolutionary process
According to Mr Accuracy reports’s new survey, global RNAi Drugs market is projected to reach US$ 268930 million in 2029, increasing from US$ 69200 million in 2022, with the CAGR of 21.4% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole RNAi Drugs market research.
Increasing incidence of chronic medical and genetic disorders such as cancer and cardiovascular diseases (CVDs) across the globe is one of the key factors driving the market growth. Moreover, rising geriatric population, who are more susceptible to these diseases, is also driving the growth of the market. In line with this, as the coronavirus disease (COVID-19) continues to spread globally, the demand for RNAi drug delivery technology has also increased significantly. Targeted drug delivery approaches, such as aptamer delivery systems, are gaining enormous traction for the delivery of antiviral drugs because they are induced by small interfering RNA (siRNA) and can inhibit the expression of viral antigens. Furthermore, various technological advancements such as the development of innovative synthetic delivery vehicles and biological carriers are expected to drive the market growth. Nanocarriers, including siRNA or microRNA (miRNA), are crucial for the development of personalized medicine and the identification of altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in nanotechnology and molecular diagnostics, and overall improvement in healthcare infrastructure are expected to further drive the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global RNAi Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Alnylam
Novo Nordisk
Eli Lilly
Alexion
Novartis
Roche
Arrowhead Pharmaceuticals Inc.
CureVac AG
Dicerna Pharmaceuticals Inc.
Gradalis Inc.
Ionis Pharmaceuticals Inc
Merck & Co. Inc.
Moderna Inc.
SBI ALApharma
Silence Therapeutics Plc
Sirnaomics Inc.
Segment by Type
siRNA
shRNA
Other
Hospital
Clinic
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The RNAi Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global RNAi Drugs market is projected to reach US$ 268930 million in 2029, increasing from US$ 69200 million in 2022, with the CAGR of 21.4% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole RNAi Drugs market research.
Increasing incidence of chronic medical and genetic disorders such as cancer and cardiovascular diseases (CVDs) across the globe is one of the key factors driving the market growth. Moreover, rising geriatric population, who are more susceptible to these diseases, is also driving the growth of the market. In line with this, as the coronavirus disease (COVID-19) continues to spread globally, the demand for RNAi drug delivery technology has also increased significantly. Targeted drug delivery approaches, such as aptamer delivery systems, are gaining enormous traction for the delivery of antiviral drugs because they are induced by small interfering RNA (siRNA) and can inhibit the expression of viral antigens. Furthermore, various technological advancements such as the development of innovative synthetic delivery vehicles and biological carriers are expected to drive the market growth. Nanocarriers, including siRNA or microRNA (miRNA), are crucial for the development of personalized medicine and the identification of altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in nanotechnology and molecular diagnostics, and overall improvement in healthcare infrastructure are expected to further drive the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global RNAi Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Alnylam
Novo Nordisk
Eli Lilly
Alexion
Novartis
Roche
Arrowhead Pharmaceuticals Inc.
CureVac AG
Dicerna Pharmaceuticals Inc.
Gradalis Inc.
Ionis Pharmaceuticals Inc
Merck & Co. Inc.
Moderna Inc.
SBI ALApharma
Silence Therapeutics Plc
Sirnaomics Inc.
Segment by Type
siRNA
shRNA
Other
Segment by Application
Hospital
Clinic
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The RNAi Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices